Walter Rayford, MD, PhD, MBA
Despite similar clinical presentations, there are disparities in risk stratification and outcomes between African-American and Caucasian patients with prostate cancer, explained Walter Rayford, MD, PhD, MBA.
State of the Science Summit™ on Genitourinary Cancers, Rayford discussed the race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.
OncLive: Could you discuss the racial genomics of prostate cancer?
: In the last decade, I have worked with a couple of pharmaceutical companies that are interested in the genomics of prostate cancer. One in particular is Myriad Genetics, and we have used their profile [tool]. It is based on a number of genes in cell cycle regulation. Using this tool, we are able to further stratify patients—particularly African-American patients—who have newly diagnosed prostate cancer. This re-stratification helps us to better select patients who are candidates for active surveillance or who require definitive treatment of their disease. We recently published this information in one of the high impact journals.
... to read the full story